Promising chemo cocktail shows hope for AML patients under 60
NCT ID NCT05906914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a three-drug chemotherapy combination (cladribine, homoharringtonine, and cytarabine) in 65 adults under 60 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how well it wiped out leukemia cells and how safe it was. Results tracked complete remission, survival, and side effects over two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost standard therapy for hard-to-treat leukemia?
- Engineered immune cells take aim at Hard-to-Treat leukemia
- New drug cocktail aims to beat back stubborn leukemia
- New pill combo aims to tackle tough leukemia
- New triple therapy aims to boost survival in frail AML patients
- New hope for older AML patients: study tests smarter drug combos to beat relapse